Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

PROFISCOV (SinoVac Brazil)
  NCT04456595		 RCTCoronaVac (SinoVac)placeboCOVID-19 prophylaxis (excluding children)NA
6195/6201 suggested
  • suggested 58 % decrease in vaccine efficacy from randomization (ITT)
  • suggested 51 % decrease in confirmed COVID (any severity)
  • suggested 84 % decrease in symptomatic Covid-19
Sinopharm Wuhan Vero cell
  NCT04510207		 RCTSinopharm WuhanplaceboCOVID-19 prophylaxis (excluding children)NA
13765/13765 suggested
  • suggested 79 % decrease in hospitalization
  • suggested 78 % decrease in symptomatic Covid-19
Xia (66)
  ChiCTR2000032459		 RCTSinopharm Beijing (BBIBP-CorV)placeboCOVID-19 prophylaxis (excluding children)NA
-/- inconclusive
    No serious adverse event was reported within 28 days post vaccination
    Sinovac Turkish Trial unpublished
          NCT04582344    		 RCTCoronaVac (SinoVac)placeboCOVID-19 prophylaxis (excluding children)NA
    		752/570 suggested
    • suggested 100 % decrease in hospitalization
    • suggested 83 % decrease in symptomatic Covid-19
    Ashmawy OBSSinopharm Beijing (BBIBP-CorV)controlCOVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 67 % decrease in symptomatic Covid-19
    Faria OBSCoronaVac (SinoVac)controlCOVID-19 prophylaxis (excluding children)critical
    		-/- suggested
    • suggested 51 % decrease in symptomatic Covid-19 but with a very low degree of certainty due to critical risk of bias
    Chile study (Aaros ) unpublished OBSCoronaVac (SinoVac)controlCOVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 80 % decrease in deaths
    • suggested 85 % decrease in hospitalization
    • suggested 67 % decrease in symptomatic Covid-19
    Hitchings OBSCoronaVac (SinoVac)controlCOVID-19 prophylaxis (excluding children)serious
    		393/393 no results
      Li OBSInactivated virus vaccinecontrolCOVID-19 prophylaxis (excluding children)critical
      		74/292 suggested
      • suggested 59 % decrease in confirmed COVID (any severity) but with a very low degree of certainty due to critical risk of bias
      Wan OBSCoronaVac (SinoVac)controlCOVID-19 prophylaxis (excluding children)critical
      		-/- safety concern
      • statistically significant 1.4-fold increase in Bell's palsy but with a very low degree of certainty due to critical risk of bias
      Bonfa
              NCT04754698      		 DESCCoronaVac (SinoVac)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
      		-/- no results

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons